EyePoint Pharmaceuticals reported a second quarter net loss of $11.5 million, or $0.11 per share, compared with a net loss of $34.4 million, or $0.62 per share, in the same quarter of 2018, according to a press release.
Total quarterly revenue was $7.2 million, with net product revenue of $6.7 million generated from sales of Yutiq (fluocinolone acetonide intravitreal implant).
Research and development expenses were approximately $4 million in the second quarter of 2019 compared with $4.8 million a year ago, and general and administrative costs increased from $4.2 million (Read more...)
Uncategorized